Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 496 to 510 of 679 results for end of life care

  1. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the

    Diagnostics guidance
    Published
    10 December 2014
    View recommendations

    Sections for DG16

  2. Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

    Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

    Technology appraisal guidance
    Published
    6 February 2018
    View recommendations

    Sections for TA504

  3. Digital technologies to support self-management of COPD: early value assessment (HTE19)

    Early value assessment (EVA) guidance on digital technologies to support self-management of COPD....

    Health technology evaluation
    Last updated
    4 February 2025
    View recommendations

    Sections for HTE19

  4. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

    Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 March 2019
    View recommendations

    Sections for TA569

  5. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief psychosocial intervention as reported by the IMPACT trial, but delivered by practitioners other than psychiatrists and in other settings, including primary care, to young people aged 12 to 18 years with mild or moderate to severe depression?

    practitioners other than psychiatrists and in other settings, including primary care, to young people aged 12 to 18 years with mild or...

    Research recommendation
    Published
    25 October 2019

  6. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

    Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic

    Diagnostics guidance
    Published
    8 May 2019
    View recommendations

    Sections for DG35

  7. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

    Technology appraisal guidance
    Published
    25 May 2011
    View recommendations

    Sections for TA223

  8. The STAK tool for preventing and treating knee stiffness (MIB252)

    NICE has developed a medtech innovation briefing (MIB) on the STAK tool for preventing and treating knee stiffness .

    Medtech innovation briefing
    Published
    9 February 2021

  9. The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)

    NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .

    Medtech innovation briefing
    Published
    19 November 2014

  10. Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

    Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA408

  11. Axonics sacral neuromodulation system for faecal incontinence (MIB259)

    NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .

    Medtech innovation briefing
    Published
    4 May 2021

  12. Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)

    Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    31 May 2023
    View recommendations

    Sections for TA892

  13. Prioritisation board decisions 2025

    at risk of CKD. They did not feel that there was a clear role for point of care testing here. Regarding monitoring, the Board did not...

  14. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

    Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Last updated
    1 January 2012
    View recommendations

    Sections for TA118

  15. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests